Granite Bio enters into an option to acquire agreement

Basel, Switzerland, and San Francisco, Calif., October 28, 2025 - Granite Bio AG, a clinical-stage immunology company, has entered into an option-to-purchase agreement with Novartis to advance the development of potential first-in-class therapies for immuno-inflammatory diseases.- Granite Bio’s pipeline includes two antibody programs designed to modulate immune pathways driving autoimmune disorders that represent significant potential market opportunities.

“This collaboration supports our scientific approach and highlights the potential of our pipeline to transform treatment paradigms across multiple autoimmune and inflammatory diseases,” said Patrick Loustau, CEO, Granite Bio. “We look forward to leveraging Novartis’s deep expertise and global development capabilities to advance these programs toward patients in need.”

***ENDS***

---